Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus
Authors:
- Slawomir AntoszczykSASlawomir Antoszczyk
- Melanie SpyraMSMelanie Spyra
- Victor Felix MautnerVMVictor Felix Mautner
- Andreas KurtzAKAndreas Kurtz
- Anat O. Stemmer-RachamimovASAnat O. Stemmer-Rachamimov
- Robert L. MartuzaRMRobert L. Martuza
- Samuel D. RabkinSRSamuel D. Rabkin
Open Access
- 26 January 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 16 (8) , 1057-1066
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive and often lethal sarcoma that frequently develops in patients with neurofibromatosis type 1 (NF1). We developed new preclinical MPNST models and tested the efficacy of oncolytic herpes simplex viruses (oHSVs), a promising cancer therapeutic that selectively replicates in and kills cancer cells. Mouse NF1− MPNST cell lines and human NF1− MPNST stemlike cells (MSLCs) were implanted into the sciatic nerves of immunocompetent and athymic mice, respectively. Tumor growth was followed by external measurement and sciatic nerve deficit using a hind-limb scoring system. Oncolytic HSV G47Δ as well as “armed” G47Δ expressing platelet factor 4 (PF4) or interleukin (IL)-12 were injected intratumorally into established sciatic nerve tumors. Mouse MPNST cell lines formed tumors with varying growth kinetics. A single intratumoral injection of G47Δ in sciatic nerve tumors derived from human S462 MSLCs in athymic mice or mouse M2 (37-3-18-4) cells in immunocompetent mice significantly inhibited tumor growth and prolonged survival. Local IL-12 expression significantly improved the efficacy of G47Δ in syngeneic mice, while PF4 expression prolonged survival. Injection of G47Δ directly into the sciatic nerve of athymic mice resulted in only mild symptoms that did not differ from phosphate buffered saline control. Two new orthotopic MPNST models are described, including in syngeneic mice, expanding the options for preclinical testing. Oncolytic HSV G47Δ exhibited robust efficacy in both immunodeficient and immunocompetent MPNST models while maintaining safety. Interleukin-12 expression improved efficacy. These studies support the clinical translation of G47Δ for patients with MPNST.Keywords
This publication has 59 references indexed in Scilit:
- Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomasInternational Journal of Oncology, 2013
- Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1Neuro-Oncology, 2012
- Tumorigenic Cells Are Common in Mouse MPNSTs but Their Frequency Depends upon Tumor Genotype and Assay ConditionsCancer Cell, 2012
- Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?Seminars in Thrombosis and Hemostasis, 2010
- Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus VectorsCancer Research, 2009
- Combination Immunotherapy for Tumors via Sequential Intratumoral Injections of Oncolytic Herpes Simplex Virus 1 and Immature Dendritic CellsClinical Cancer Research, 2008
- Nerve-Sparing Therapy with Oncolytic Herpes Virus for Cancers with Neural InvasionClinical Cancer Research, 2007
- Germline and somaticNF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs)Human Mutation, 2007
- Oncolytic HSV Armed with Platelet Factor 4, an Antiangiogenic Agent, Shows Enhanced EfficacyMolecular Therapy, 2006
- Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.2002